HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancer
HighField Biopharmaceuticals a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the first patient has been dosed in a Phase 1b/2 trial of HF1K16 for recurrent and refractory glioma. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA).
